Information Provided By:
Fly News Breaks for September 19, 2018
NVO, ZEAL
Sep 19, 2018 | 08:27 EDT
Needham analyst Alan Carr raised his price target on Zealand Pharma (ZEAL) to $29 and kept his Buy rating after its announced Phase 3 trial results of dasiglucagon in Acute Severe Hypoglycemia. The analyst notes that the trial met its primary median time endpoint for glucose recovery, adding that the rapid response is comparable to the currently marketed Glucagen made by Novo Nordisk (NVO). With phase 3 trial expected to be launched this month, Carr anticipates Zealand's potential commercialization of dasiglucagon to come in 2020 and for peak sales to reach $360M in 2030.